<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01434888</url>
  </required_header>
  <id_info>
    <org_study_id>201150</org_study_id>
    <secondary_id>2011-001778-24</secondary_id>
    <nct_id>NCT01434888</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops</brief_title>
  <official_title>A Phase I, Randomized, Double-masked, 3-period Cross-over Clinical Study to Compare the Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops to Those of Preservative-free Tafluprost 0.0015% and Timolol 0.5% Eye Drops in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Oy</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen Oy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the pharmacokinetics, safety and tolerability
      of the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% (FDC)
      to those of preservative-free tafluprost 0.0015% and timolol 0.5% eye drops in healthy
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics after single and repeated administration of preservative-free FDC, tafluprost and timolol eye drops.</measure>
    <time_frame>There are 3 cross-over treatment periods, plasma concentrations will be measured on Day 1 and Day 7</time_frame>
    <description>The primary evaluation of pharmacokinetics will be based on the plasma concentration of tafluprost acid and timolol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability after single and repeated administration of preservative-free FDC, tafluprost and timolol eye drops.</measure>
    <time_frame>Day 1 and Day 7 of treatment periods I, II and III.</time_frame>
    <description>The changes from screening/baseline will be evaluated in following variables:visual acuity, IOP, biomicroscopy and ophthalmoscopy findings and drop discomfort.
Adverse events will be followed from screening to post-study visit.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Tafluprost 0.0015%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Timolol 0.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed-dose combination of tafluprost 0.0015% and timolol 0.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preservative free tafluprost 0.0015% eye drops</intervention_name>
    <description>Preservative free tafluprost eye drops will be administered once daily at 09:00 into both eyes for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.</description>
    <arm_group_label>Tafluprost 0.0015%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preservative free timolol 0.5% eye drops</intervention_name>
    <description>Preservative free timolol eye drops will be administered into both eyes twice daily at 9:00 and 21:00 for seven days</description>
    <arm_group_label>Timolol 0.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops</intervention_name>
    <description>Preservative free fixed-dose combination eye drops will be administered into both eyes once daily at 9:00 for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.</description>
    <arm_group_label>Fixed-dose combination of tafluprost 0.0015% and timolol 0.5%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 to 45 years

          -  Good general health

          -  Meet best corrected ETDRS visual acuity

        Exclusion Criteria:

          -  Significant systemic or ocular disease

          -  History of eye surgery, including refractive surgery

          -  Allergy or hypersensitivity to study drug

          -  Low heart rate (&lt;50 bpm)

          -  Clinically relevant low blood pressure

          -  Asthma

          -  Bradycardia

          -  Use of contact lenses within one week prior to screening or during the study

          -  Clinically significant obesity (body mass index &gt; 30 kg/m2)

          -  Blood donation within 2 months prior to screening

          -  Females who are pregnant or lactating and females not using adequate contraceptives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kuopio University Hospital Eye Clinic</name>
      <address>
        <city>Kuopio</city>
        <zip>70200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2011</study_first_submitted>
  <study_first_submitted_qc>September 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2011</study_first_posted>
  <last_update_submitted>June 7, 2012</last_update_submitted>
  <last_update_submitted_qc>June 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Timolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

